Clinical trials: Cancer Disease Progression
Peritoneum; Carcinomatosis, Peritoneal Neoplasms
Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol Chemotherapy -
This is a study, where the efficacy of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) against peritoneal metastases will be evaluated.
- Conditions
- Peritoneum; Carcinomatosis, Peritoneal Neoplasms, Peritoneal Metastases, Chemotherapy Effect
- Trial name
- PIPAC-OPC2 (NCT03287375)
- Testing
- PIPAC
- Where
- Denmark
- Volunteers
- 143 people
- Sponsor
- Michael Bau Mortensen
Neuroendocrine Tumors
PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment
This is a retrospective study. The analysis includes patients with advanced neuroendocrine cancer (NEN) treated with systemic therapy, because of inoperable primary tumor or/and metastasis, clinical, imaging, biochemical disease…
- Trial name
- NCT04331912
- Where
- 2 sites in Poland
- Volunteers
- 100 people
- Sponsor
- University of Warmia and Mazury
High-Grade Squamous Intraepithelial Lesions, Neoplasm Regression, Spontaneous
Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
Consecutive inclusion and collection of information for all women attending the Cervical Disease Unit with an histological diagnosis of grade 2 or grade 3 CIN during the last 5 years, from January 2012 to December 2016, which…
- Conditions
- High-Grade Squamous Intraepithelial Lesions, Neoplasm Regression, Spontaneous, Disease Progression, Papillomavirus Infections
- Trial name
- NCT04115787
- Where
- Spain
- Volunteers
- 104 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Gastric (Stomach) Cancer, Biological Therapy
The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
This project employs a prospective, double-blind, randomized controlled trial methodology to comparatively analyze the safety and survival outcomes of human umbilical cord blood RAK cells applied in advanced gastric cancer.
- Conditions
- Gastric (Stomach) Cancer, Biological Therapy, Immunotherapy
- Trial name
- RAK in GC (NCT07212933)
- Testing
- RetroNectin active Killer cells, TAS-102 (trifluridine and tipiracil, Lonsurf®)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese PLA General Hospital
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
This phase II trial studies how well anakinra works in preventing severe chimeric antigen receptor T-cell-related encephalopathy syndrome after chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma that…
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Progressive Disease, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04205838
- Testing
- Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Head and Neck Squamous Cell Carcinoma
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study
This is a prospective, single-arm, multi-center, Phase II clinical trial evaluating the efficacy and safety of neoadjuvant becotatug vedotin (an anti-EGFR antibody-drug conjugate) combined with pucotenlimab (HX008, an anti-PD-1…
- Trial name
- GATEWAY (NCT07589049)
- Testing
- Becotatug Vedotin, Pucotenlimab
- Where
- 12 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Renal Cell Carcinoma Metastatic
A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line
With the advent of immunotherapy, standard first-line treatment for patients with renal cell carcinoma is now an association with an immune checkpoint inhibitor.
- Trial name
- AxiPRO (NCT04764487)
- Testing
- KidneyPRO, standard follow-up
- Where
- 13 sites in France
- Volunteers
- 178 people
- Sponsor
- Weprom
Locally Advanced Breast Cancer, Metastatic Breast Cancer
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer.
- Trial name
- EFECT (NCT00065325)
- Testing
- Fulvestrant, Exemestane
- Where
- 117 sites in United States, Argentina and 13 more
- Volunteers
- 694 people
- Sponsor
- AstraZeneca
Multiple Myeloma
CART-19 for Multiple Myeloma
The primary goals: determine the safety, tolerability and engraftment potential of CART-19 T cells in patients undergoing salvage ASCT after early relapse following first ASCT.
- Trial name
- NCT02135406
- Testing
- CART-19 T cells
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Pennsylvania
Prostate Cancer
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug UniCAR02-T-pPSMA in patients with progressive disease…
- Trial name
- NCT04633148
- Testing
- Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), UniCAR02-T-pPSMA
- Where
- 4 sites in Germany
- Volunteers
- 16 people
- Sponsor
- AvenCell Europe GmbH
Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment
TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
In this phase I trial, patients with relapsed or refractory multiple myeloma will receive standard autologous stem cell transplant conditioned with high dose melphalan.
- Trial name
- BMT-03 (NCT02043847)
- Testing
- Total Marrow Irradiation, Melphalan, Filgrastim (G-CSF)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Illinois Chicago
Cachexia, Cancer
Impact of Nutritional Intervention in Indian Female Cancer Cachexia Patients
The main aim of the study is to assess the effectiveness of tailored nutritional intervention in delaying the progression of cachexia to refractory cachexia in adult female cancer patients.
- Trial name
- NCT02350855
- Testing
- Improved Atta, Nutritional counseling, Physical activity counseling
- Where
- 2 sites in India, United Kingdom
- Volunteers
- 62 people
- Sponsor
- University of Westminster
BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
This phase I/II trial studies the best dose and side effects of encorafenib, cetuximab, and nivolumab and how well they work together in treating patients with microsatellite stable, BRAFV600E gene mutated colorectal cancer that…
- Conditions
- BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma
- Trial name
- NCT04017650
- Testing
- Cetuximab, Encorafenib, Nivolumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
CD19 Positive, CD22 Positive
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
This phase I/II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia…
- Conditions
- CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease
- Trial name
- NCT04029038
- Testing
- Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma (MM)
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM).
- Trial name
- NCT07029776
- Testing
- teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Arkansas
Metastatic Renal Cell Carcinoma ( mRCC)
Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC
The goal of this clinical trial is to learn whether the timing of surgery (cytoreductive nephrectomy) improves outcomes when combined with immunotherapy (ipilimumab and nivolumab) in adults with metastatic clear cell renal cell…
- Trial name
- IVE in mRCC (NCT07233668)
- Testing
- Ipilimumab plus Nivolumab, Cytoreductive Nephrectomy
- Volunteers
- 172 people
- Sponsor
- Seoul National University Hospital
Progression-free Survival Was Defined From Date of Surgery to Disease Progression Post-surgery or Death or Last Follow-up, Overall Survival Was Defined as Time From Surgery to Death From Any Cause or Last Follow-up
Observational, Bivariate Analysis of Clinical Big Data in Patients With Cervical Cancer
This is a large non-interventional observational bidirectional study planned to collect clinically relevant data and prognostic follow-up information of patients with cervical cancer who were seen at our center from 2010.01.01 to…
- Trial name
- NCT06480617
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Anhui Provincial Hospital
Uterine Cervical Neoplasms
Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer
The main purpose of this study was to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy.
- Trial name
- NCT04246489
- Testing
- Bintrafusp alfa
- Where
- 73 sites in United States, Argentina and 10 more
- Volunteers
- 146 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Breast Cancer
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899548
- Testing
- DNA methylation analysis, microarray analysis, polymerase chain reaction
- Where
- 4 sites in United States
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bladder Cancer, Carcinoma, Transitional Cell
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
Primary Objective: To analyse time to tumor progression in patients cystectomized for locally advanced transitional cell carcinoma (TCC) of the bladder, who are not suitable for cisplatin-based chemotherapy (i.e.
- Trial name
- NCT00146276
- Testing
- gemcitabine
- Where
- Germany
- Volunteers
- 178 people
- Sponsor
- Association of Urologic Oncology (AUO)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.